Weight loss drug cost statistics 2026: list prices, cash prices, out-of-pocket costs and coverage

list price (WAC) of a four-pen package of Wegovy injection, the same for every dose¹

The Wegovy pill has the same list price per 30-tablet bottle. Novo Nordisk pricing page dated March 2026.

list price (WAC) of an Ozempic pen package, the same for every dose²

Novo Nordisk pricing page dated May 2026.

per month price of Zepbound cited by the White House before its November 2025 agreement with Eli Lilly³

The same fact sheet cited prior monthly prices of $1,000 for Ozempic and $1,350 for Wegovy.

annual list price of Wegovy ($1,300 a month) cited by KFF in 2024⁴

new list price for Wegovy and certain Ozempic doses from January 1, 2027, a reduction of about 50% for Wegovy and 35% for Ozempic⁵

standard monthly self-pay price for Wegovy and Ozempic since November 17, 2025, down from $499⁶

Ozempic 2 mg stayed at $499 per month.

introductory monthly self-pay price for the first two fills of the lowest Wegovy and Ozempic doses for new patients⁶

Launched November 17, 2025, initially available through March 31, 2026.

monthly self-pay price of Wegovy HD (7.2 mg), available nationwide since April 2026⁷

monthly self-pay price range for the Wegovy pill, depending on dose⁵

monthly self-pay price range for Zepbound vials through LillyDirect: $299 for 2.5 mg, $399 for 5 mg and $449 for 7.5 mg to 15 mg⁸

Lower prices for higher doses require refilling within 45 days.

monthly self-pay price for the lowest dose of Foundayo (orforglipron), Lilly's oral GLP-1 approved in April 2026⁹

average monthly price of Wegovy and Ozempic on TrumpRx.gov, as low as $199 depending on dose¹⁰

The same February 2026 fact sheet lists Zepbound at an average of $346 (as low as $299) and the Wegovy pill as low as $149.

of adults who have taken a GLP-1 say the drugs were difficult to afford, including 55% of those with health insurance¹¹

KFF poll fielded October 27 to November 2, 2025. About 1 in 4 said very difficult.

of GLP-1 users with health insurance say they paid the full cost themselves¹¹

of GLP-1 users say insurance covered part of the cost and the full cost, respectively¹²

of adults who have taken a GLP-1 say they stopped because of the cost¹²

lowest monthly cost for qualifying commercially insured patients using savings offers for Wegovy and Ozempic, respectively⁶

of Americans with employer-sponsored insurance lack coverage for obesity medications, according to Eli Lilly⁹

Company estimate stated in an April 2026 press release.

of firms with 5,000 or more workers covered GLP-1s primarily for weight loss in 2025, up from 28% in 2024¹³

of firms with 200 to 999 workers covered GLP-1s primarily for weight loss in 2025, compared with 30% of firms with 1,000 to 4,999 workers¹³

of firms with 5,000 or more workers that cover GLP-1s for weight loss say it had a significant impact on prescription drug spending¹³

The figure was 43% for firms with 1,000 to 4,999 workers (2025).

of firms with 5,000 or more workers say GLP-1 use for weight loss was higher than expected¹³

44% of firms with 1,000 to 4,999 workers said the same (2025).

of firms with 200 or more workers that do not cover GLP-1s for weight loss say they are not likely to start in the next 12 months¹³

1% said very likely and 24% somewhat likely (2025).

of employers with 500 or more employees covered GLP-1 weight-loss drugs in 2025, up from 44% in 2024¹⁴

Mercer also found large-employer prescription drug spending rose 9.4% in 2025.

monthly copay for eligible Medicare beneficiaries for Wegovy, Foundayo or Zepbound KwikPen under the Medicare GLP-1 Bridge, starting July 1, 2026¹⁵

Eligibility includes a BMI of 35 or higher, or lower BMI thresholds with certain conditions; prior authorization is valid through December 31, 2027. The copay does not count toward the Part D out-of-pocket limit.

net monthly price manufacturers agreed to for GLP-1s under the Medicare GLP-1 Bridge¹⁶

seniors saved a combined $216 million on GLP-1 drugs in the first two months of the $50 Medicare program¹⁷

Administration figure from a September 2026 White House fact sheet.

gross Medicare Part D spending on GLP-1 drugs in 2024, before rebates¹⁸

Part D could not cover drugs used solely for weight loss before the Bridge, so this spending reflects covered uses such as type 2 diabetes. Ozempic alone made up 47%.

state Medicaid programs covered GLP-1s for obesity under fee-for-service as of January 2026, down from 16 in October 2025¹⁹

estimated 10-year cost of Medicare Part D coverage of obesity drugs, as cited by KFF¹⁶